Medication Regimen Assessment for Narcolepsy, Bipolar I, and PTSD

Modafinil Dosing for Narcolepsy

The American Geriatrics Society recommends modafinil 200-400 mg/day for elderly patients with narcolepsy, with typical starting doses of 100 mg upon awakening and weekly titration as needed 1, 2
Modafinil has gained favor as first-line treatment for narcolepsy due to its efficacy, favorable side effect profile, and lack of rebound hypersomnia or significant abuse potential 1, 2

The BMJ recommends pregabalin doses of 150-600 mg/day for anxiety disorders, and the current dose of 25 mg three times daily is substantially below any therapeutic range studied for anxiety or PTSD-related symptoms 3
The evidence base for pregabalin in PTSD is limited, and when studied, doses were considerably higher 3

The American Academy of Sleep Medicine recommends against long-term benzodiazepine use in elderly patients due to increased risk of falls, cognitive impairment, paradoxical reactions, and dependence 4, 5, 6
Prazosin (1-6 mg at bedtime) is a recommended alternative for PTSD-related nightmares, with stronger evidence 4, 5, 7

The Annals of Internal Medicine recommends duloxetine 60 mg/day as a therapeutic dose for depression and anxiety, and the current dose of 30 mg BID may be suboptimal 8
The Journal of the American Academy of Child and Adolescent Psychiatry recommends against antidepressant monotherapy in bipolar I disorder due to risk of manic episodes or mood destabilization, and a mood stabilizer should be established before continuing duloxetine 9

The Journal of the American Academy of Child and Adolescent Psychiatry recommends adding a mood stabilizer, such as lithium or valproate, as the foundation for bipolar I treatment, and alternatively, an atypical antipsychotic like aripiprazole, quetiapine, or olanzapine may be considered 9
A slow taper plan for clonazepam should be developed while introducing prazosin for PTSD nightmares, starting at 1 mg at bedtime and titrating to 2-6 mg based on response 4, 5

Weekly assessment for manic/hypomanic symptoms is recommended when adjusting medications, particularly when establishing a mood stabilizer 9
Monitoring for changes in excessive daytime sleepiness, cataplexy, and nightmare frequency is recommended, as well as assessing for benzodiazepine-related impairment during taper 1, 2, 4, 6